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Abstract
Background: Human dopamine b-hydroxylase (DBH) is an important therapeutic target for complex traits. Several single
nucleotide polymorphisms (SNPs) have also been identified in DBH with potential adverse physiological effect. However,
difficulty in obtaining diffractable crystals and lack of a suitable template for modeling the protein has ensured that neither
crystallographic three-dimensional structure nor computational model for the enzyme is available to aid rational drug
design, prediction of functional significance of SNPs or analytical protein engineering.
Principal Findings: Adequate biochemical information regarding human DBH, structural coordinates for peptidylglycine
alpha-hydroxylating monooxygenase and computational data from a partial model of rat DBH were used along with logical
manual intervention in a novel way to build an in silico model of human DBH. The model provides structural insight into the
active site, metal coordination, subunit interface, substrate recognition and inhibitor binding. It reveals that DOMON
domain potentially promotes tetramerization, while substrate dopamine and a potential therapeutic inhibitor nepicastat are
stabilized in the active site through multiple hydrogen bonding. Functional significance of several exonic SNPs could be
described from a structural analysis of the model. The model confirms that SNP resulting in Ala318Ser or Leu317Pro
mutation may not influence enzyme activity, while Gly482Arg might actually do so being in the proximity of the active site.
Arg549Cys may cause abnormal oligomerization through non-native disulfide bond formation. Other SNPs like Glu181,
Glu250, Lys239 and Asp290 could potentially inhibit tetramerization thus affecting function.
Conclusions: The first three-dimensional model of full-length human DBH protein was obtained in a novel manner with a
set of experimental data as guideline for consistency of in silico prediction. Preliminary physicochemical tests validated the
model. The model confirms, rationalizes and provides structural basis for several biochemical data and claims testable
hypotheses regarding function. It provides a reasonable template for drug design as well.
Citation: Kapoor A, Shandilya M, Kundu S (2011) Structural Insight of Dopamine b-Hydroxylase, a Drug Target for Complex Traits, and Functional Significance of
Exonic Single Nucleotide Polymorphisms. PLoS ONE 6(10): e26509. doi:10.1371/journal.pone.0026509
Editor: Vladimir N. Uversky, University of South Florida College of Medicine, United States of America
Received August 5, 2011; Accepted September 28, 2011; Published October 20, 2011
Copyright:  2011 Kundu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Financial assistance from Department of Biotechnology (DBT,http://dbtindia.nic.in/index.asp#), Government of India in the form of research grant to
SK (BT/01/COE/07/UDSC) is especially acknowledged. Research and Development funding by University of Delhi (www.du.ac.in) University are also duly
acknowledged. Financial assistance to MS in the form of research fellowship by University Grants Commission (www.ugc.ac.in), Government of India is also
acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sumankundu7@ gmail.com
Introduction
Human dopamine b-hydroxylase (DBH), a constituent of cate-
cholamine biosynthetic pathway, catalyzes the conversion of
dopamine to noradrenaline or norepinephrine [1]. The enzyme is
expressed in noradrenergic nerve terminals of the central and
peripheral nervous system, as well as in chromaffin cells of adrenal
medulla. It is an important therapeutic target that has been
associated to and implicated in several diseases and pathological
conditions including Parkinson’s, Huntington’s chorea, hyperten-
sion, depression, cardiac heart failure, Tourette syndrome, etc. [2–
5]. Inhibition of DBH may allow treatment of some of such
disorders like hypertension and congestive heart failure [6–8]. DBH
is inhibited by disulfiram, tropolone, etamicastat, nepicastat and
several others. [8–11]. However, they often result in side effects or
adversities and are frequently non-responsive to specific population
and hence the search for new inhibitors with desired specificity and
intensity is always on. Moreover, there has been no structural basis
forunderstandingofsubstratebindingtohumanDBHthat canhelp
envisage better inhibitors. Reports of the success of inhibitors such
asnepicastat[11]aspotentialdrugsarenotsubstantiatedbyanalysis
of their mechanism of binding to DBH that can help design of
analogues or chemical modifications to enhance their efficacy.
On the other hand, a number of single-nucleotide polymorphisms
(SNPs) have been identified for DBH [1,4,12–17]. However, their
functional significance is largely unknown. There have also been
contradictory reports regarding the influence of SNPs on enzyme
activity. Thus, while Ishii et al. [18] reported that non-synonymous
SNP resulting in A318S mutation alter enzyme activity, Li et al. [7]
showed that the mutation do not influence enzyme activity at all. There
has been no structural validation, either way, for such contrasting
results. In addition, functional significance of domains of DBH other
than the ones containing the active site has not yet been elucidated.
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screening, understanding functional significance of SNPs and
domains in DBH is a three dimensional structure of the enzyme.
As of date, no crystal structure is reported for the enzyme (www.
pdb.org) resulting in lack of global structural insight, though
wealth of biochemical data and in silico studies of the active site
domain are available for DBH [19–24].
The use of biochemical knowledge with regard to DBH for a
structural insight was contemplated. DBH is a colorless monoox-
ygenase containing a total of eight disulfide bonds [25]. The active
unit of the enzyme is a tetramer of molecular weight 290000 Da,
formed by non-covalent interactions between two dimers held
together by two interchain disulfide linkages [19,26,27]. The
enzymatic reaction is known to proceed through redox reaction in
which the two Cu (II) centers of the resting enzyme are first
reduced by ascorbate to an active Cu (I) state [21,28]. Active site
structure has been probed by EPR spectroscopy and other
methods to obtain information on metal-binding amino acid
residues and the coordination and geometry of the two copper
atoms [20,21,29–35]. PHM (Peptidylglycine alpha-hydroxylating
monooxygenase; 1PHM), with a 27% sequence identity to DBH,
was shown to be the evolutionary precursor of the enzyme [36].
The three-dimensional coordinates and mechanistic data for the
chemical and electron transfer steps in catalysis of PHM were thus
used to model a partial structure of rat DBH to show the position
of the catalytically important residues in the enzyme [28].
However, the model displayed Cu binding domains only and a
structure for full-length protein is still lacking. The difficulties in
crystallizing the protein have compounded the problem.
We hypothesized that combination of biochemical information,
computational data, and sequences of DBH available from multiple
species can be used to map a three-dimensional structure of the
human counterpart of the enzyme in silico. The idea was to use a
subset of the available biochemical information as guidelines to
build a model that can be subsequently validated by observing
whether the structure successfully corroborates the other subset of
the biochemical data. In the current investigation, an attempt has
been made to model the complete structure of human DBH with
experimental evidences as guiding principles for computational
framework. The model has been built into a tetramer revealing
domain organization, oligomerization and active site details. Also,
the locations of SNPs thought to be important for activity have been
identified and certain controversial results analyzed. Substrate and
inhibitor docking in the active site have also been inspected. This is
the first report of structural details of human DBH obtained in silico
and will expedite better understanding of the structure-function
relationship of the enzyme, functional significance of SNPs and
rational design of potentially important therapeutics. The novel
approach of building the model using biochemical information in
conjunction with other commonly used techniques is an important
step towards solving protein structures in general.
Results and Discussion
Primary Structure Analysis
The human DBH sequence from NCBI database, with accession
number P09172, was targeted for investigation. Protein sequence
BLAST against non-redundant database in NCBI showed that
DBH share similarity with peptidylglycine alpha-hydroxylating
monooxygenase (PHM) with 27% sequence identity. PHM was
shown to be the evolutionary precursor of DBH [36]. Bhaduri et al.
[37] analyzed DBH sequences from twelve organisms, which were
revisited for the sake of current investigation (Table S1). Human
DBH sequence shares maximum identity (86%) with Sus scrofa (pig).
Significant similarity was also obtained with other mammalian
species indicating the significance of this protein in general.
Amino acid residues absolutely conserved in DBH proteins were
identified from a multiple sequence alignment shown in Figure 1
and partly in Bhaduri et al. [37]. Only 45 of the total residues are
completely conserved when species as diverse as the Drosophila and
Homarus (lobster) are included in the comparison. However, 350 of
the total residues were completely conserved when only species
with significant alignment were used for comparison. All
conserved residues are highlighted in purple color. The five His
residues and one Met residue that could be important for
interaction with the active site Cu ions, by analogy to PHM
[29,37], are highly conserved except in case of Aedes aegypti and
Culex quinquefasciatus where one of the His is replaced by Asn and
Lys, respectively. The His and Met residues that putatively interact
with the other copper centre, by comparison to PHM [28], are
also replaced in both the above organisms. Fourteen Cys residues
that possibly form structurally important disulfide bonds, as
evidenced by biochemical investigation [25], are highly conserved.
However, in case of Drosophila, Aedes, Homarus and Culex, the latter
two Cys residues are absent indicating that interchain disulfides
are probably absent in the corresponding proteins. This signifies
that in lower organisms, DBH might not undergo oligomerization
and may be functional in monomeric form. Prigge et al. [28]
demonstrated the catalytically important residues in rat DBH
based on their homology with PHM (PDB ID: 1PHM). It was
shown that Glu268, Glu369 and Tyr494 form complex hydrogen
bonding network with substrate. These residues are highly
conserved (highlighted in light blue) except in case of Aedes and
Culex where none of the three residues are present. Due to such
differences with DBH of lower organisms, our investigation will be
restricted to comparisons of human DBH to mammalian DBH
only, whenever required.
Primary structure of human DBH is 617 amino acids in length
with 15 cysteine residues of which 14 are involved in disulfide bond
formation [25]. Cys154-Cys596, Cys232-Cys283, Cys269-Cys295,
Cys390-Cys503, Cys394-Cys565 and Cys466-488 are involved in
intramolecular disulfide bonds whereas two cysteines, at positions
528 and 530, are involved in intermolecular disulfide bonds
(Figure 2a). The location of these residues and disulfides served as
milestones in model building, frequently guiding the orientation of
peptide backbone, proximity of amino acid side chains and subunit
interaction, especially since all intrasubunit disulfides are conserved
across species (Figure 1). DBH contains a total of 64 negatively
chargedresidues(Asp +Glu)and 52positivelychargedresidues(Arg
+ Lys) giving protein an overall charge of 212. Since charged
residues in globular proteins mostly reside on surfaces, they also
provide guidelines for protein model building.
Search for domain architecture of DBH using CDART [38]
shows that DBH consists of three major domains as shown in
Figure 2a, mentioned in Table S1 and also reported earlier [37].
The first major domain on the N-terminal side is DOMON
domain [37,39], which is located from position 57 to 173.
Preceding this is a signal sequence. Following the DOMON
domain is Copper type II ascorbate-dependent monooxygenase N-
terminal domain located from position 196 to 344 followed by
Copper type II ascorbate-dependent monooxygenase C-terminal
domain located from position 359 to 526 [37]. Between the
DOMON domain and the monooxygenase domains is a short
stretch of amino acids as well. The sequence also showed a C-
terminal tail without sequence homology to any known domain.
There are about 182 more sequences reported in NCBI with
similar domain architecture consisting of one DOMON domain
followed by two monooxygenase domains.
First 3D Model of Human DBH
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and transmembrane proteins from both plants and animals and is
about 110–125 residues in length [39]. It is found in 1–4 copies and
in association with other domains such as Cu ascorbate-dependent
monooxygenase,Reelindomain,SEAdomain,trypsininhibitor-like
domain (TIL) and epidermal growth factor domain. Structure for
DOMON domainis not available; however, it has beenproposedto
form a b-sandwich structure with 7–8 core strands [37,39]
supported by a buried core of conserved hydrophobic residues.
Human DBH DOMON domain modeled using I-Tasser conforms
to this hypothesis and shows a beta-sandwich structure (Figure 2b).
This domain may function as a module in mediating a range of
extracellular adhesive interactions and might also be needed for the
non-covalent tetramerization of DBH or for interaction between
DBH and specific proteins [37,39]. In general, DOMON domain
has been shown to be involved in heme and sugar recognition [40].
Human DBH showed two glycosylation sites, one at position 64
(present within the DOMON domain) and the other at 184 (located
close to this domain) [41].
The two monooxygenase domains form the catalytic unit of the
enzyme and eachone binds to one Cu atom required for the activity
of the enzyme. A crystal structure for this domain from PHM is
known [28]. In the enzymes of the PHM family, N-terminal
domains are approximately 140 residues long and their structural
unit consists of a b-sandwich of two antiparallel b-sheets composed
of approximately ten b-strands. There are three disulfide links
connecting the strands and loops as seen in rat PHM (PDB ID:
1PHM; Figure 2c); however in case of bovine DBH this domain
contains only two disulfide links and the third link is missing as
there is no Cys residue at the corresponding position [25]. This
domain binds one Cu atom designated as CuA, which is believed
to be involved in ascorbate binding. The C-terminal domain is
approximately 160 residues long and its structural unit also consist
of a b-sandwich comprising two antiparallel b-sheets composed of
approximately twelve b-strands and one 310 helix. Though this
domain consists of two disulfide links in the enzymes of PHM family
(Figure 2c)butincaseofbovineDBHitcontainsthreedisulfidelinks
[25]. It also binds one Cu atom designated as CuB, which is
supposed to be the site for substrate binding and hydroxylation.
Human DBH, as evident from sequence comparison, should exhibit
many of these characteristics in its three-dimensional model.
Secondary Structure Analysis
The secondary structure prediction of human DBH, performed
using PredictProtein tool, classified the overall protein as ‘‘Mixed’’
with 61% % of total amino acids being in the form of loops. The
high content of loops in the protein architecture with putative
flexible structure might prevent formation of diffractable crystals.
The predicted b-sheet and a-helical contents were 30% and 9%,
respectively, as represented schematically in Figure 3. The
prediction matches well with structural data obtained for
individual domains from other sources like PHM (Figure 2c) or
models of individual domains of human DBH like DOMON
domain (Figure 2b). So secondary structural information can be
relied upon for building model whenever ambiguity arises or
restrictions are required to assign conformation in three-dimen-
sion. Further, primary sequence analysis and secondary structure
predictions are more robust than tertiary structure predictions and
hence the former were given priority over the later whenever
contradictions arose in the current investigation.
Model Building and Validation – Three-dimensional
structure
ModelingDBHprotein structure usingcomputationaltechniques
such as homology modeling and threading was not feasible as there
Figure 1. Multiple sequence alignment of DBH sequences. Eleven DBH sequences (horse, pig, cattle, mouse, rat, dog, zebra fish, drosophila,
Aedes aegypti, mosquito, lobster) were aligned to the human DBH sequence [37]. Residues that are identical are highlighted in purple font; Cys
residues involved in intramolecular disulfide bonds are highlighted in yellow color while the Cys residues involved in interchain disulfide links are
colored green. Copper binding sites are highlighted in red color.
doi:10.1371/journal.pone.0026509.g001
First 3D Model of Human DBH
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the enzyme. PHM is the only enzyme that exhibits homology to the
N- and C-terminal monooxygenase catalytic domains of DBH.
AttemptwasmadetomodelDBHusingab-initioapproach(Figure4).
However, the model was not reliable as none of the disulfide
linkages reported experimentally [25] were observed in the model.
The cysteine residues were not in proximity for formation of
covalent linkage indicating that the backbone conformation was
erroneous. Moreover, the region from 39–209 (region containing
DOMON domain; represented in green in Figure 4) was modeled
as loop. This contradicts secondary structure prediction depicted in
Figure 3 as well as the structural organization obtained for human
DOMON domain when modeled individually (Figure 2b) or as
proposed for such domains in other proteins like PHM [39]. The
model was thus unacceptable.
The problem was subsequently overcome by modeling smaller
fragments of proteins as mentioned in the methods section. I-
TASSER (ab-initio method) modeled the individual fragments in
agreement with the secondary structure predictions (Figures 5a–
5e) except fragment 3 (amino acid sequence 174–195), which was
modeled as helical structure but is predicted to be loop (Figure 5c).
The basic idea was then to assemble the ab-initio modeled
fragmentsaroundthehomologymodeled fragment 4,the N- and C-
terminal monooxygenase catalytic domain. The complete model
was successfully assembled by reproducing the torsion angles of the
individual fragments to the extended polypeptide chain and
changing the angles wherever necessary to fulfill geometric
requirements. Orientation of fragment 3 (residues 174–195;
Figure 5c), the loop region between the DOMON domain and
the N-terminal monooxygenase domain, was important as the
orientation of this loop decides where rest of the structure goes.
Loop database present within Swiss-PDB Viewer was tried to
predict the structure of this region (174–195) but the predictions
could not orient the loop properly. The clue to orient this loop
region was obtained from the secondary structure map (Figure 3).
There is a b-sheet predicted in the regions 50–53 and 193–197.
Interestingly, there is no b-sheet in the region 50–53 in the absence
of the rest of the structure as in seen in the model for fragment 1,
indicated by arrow in Figure 5a and in Figure 5f. Also, all other
predicted b-strands belong to one or other of the three domains
exceptthestrand predictedbetween 193–197.So,itwasargued that
these two strand regions must interact to form a b-sheet in the DBH
molecule. Many different loop orientations were then tried by
manually adjusting the torsion values to bring these strands
together. However, the sheet was seen in only one particular
orientation depicted in Figure 5g and was thus acceptable. The N-
terminal structure (sequence from 1–197) generated was then
assembled with the 4
th fragment. The homology modeled 4th
fragment contained only two disulfide links between Cys232-
Cys283andCys466-Cys488.However,ithasbeenreportedthatthe
two domains together are involved in five disulfide linkages between
Cys232-Cys283, Cys269-Cys295, Cys390-Cys503, Cys394-Cys565
and Cys466-Cys488 [25].Conforming to experimental results, the
structure was changed locally to introduce disulfide link between
Figure 2. Domain organization of human DBH sequence. A. Domain architecture of human DBH obtained using CDART. Shown are the three
domains: DOMON domain (sequence position 57–173), Cu type II monooxygenase N-terminal domain (sequence position 196–344), and Cu type II
monooxygenase C-terminal domain (sequence position 359–526). Intramolecular disulfide bridges are shown by closed lines while the two open lines
correspond to cysteine residues involved in interchain disulfide bridges. B. Structure of DOMON domain modeled using I-TASSER server. C. Structure
of the two Cu type II monooxygenase N- and C-terminal domains based on reduced peptidylglycine alpha-hydroxylating enzyme (PDB ID: 1PHM). The
two Cu atoms are represented as red spheres. Residues forming disulfide links are colored by atom type (carbon is cyan, nitrogen is blue, oxygen is
red and sulfur is yellow).
doi:10.1371/journal.pone.0026509.g002
First 3D Model of Human DBH
PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e26509Figure 3. Secondary structure distribution of human DBH sequence obtained from PredictProtein server. Purple arrows indicate b-
strand; orange cylinders indicate a-helix while loops are depicted as green lines. The numbers indicate the position within the sequence.
doi:10.1371/journal.pone.0026509.g003
Figure 4. Model of human DBH obtained using I-TASSER server. The cysteine residues are colored by atom type (carbon is cyan, nitrogen is
blue, oxygen is red and sulfur is yellow). Region of structure from 39–209 is colored green.
doi:10.1371/journal.pone.0026509.g004
First 3D Model of Human DBH
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th fragment was based on introduc-
ing two disulfide linkages between Cys394-Cys565 and Cys154-
Cys596. Thus, all reported disulfide linkages were modeled except
the one between Cys390-Cys503. Introduction of this particular
disulfide link required lot of changes in the domain structure, which
resulted in major distortion of the overall configuration of the C-
terminal domain. So it was left undone. Literature search showed
that there could be erroneous determination of the number of
disulfidebridgesinsolutionforproteins,whichwere laterrectifiedin
three dimensional structures of those proteins [42]. The Cys390-
Cys503 disulfide bond could be an experimental aberration as well
and the final verification will have to await experimental three
dimensional structure of the enzyme. Figure 6a shows the complete
model of human DBH generated with all disulfide links highlighted.
DOMON domain, Cu type II N-terminal domain and Cu type II
C-terminal domains are highlighted in green, blue and red color
respectively. Quality of the overall structure was estimated by
calculating the Ramachandran plot. Approximately 91% residues
Figure 5. Structure of DBH protein fragments modeled using I-TASSER and EsyPred3D. A. Fragment 1 spanning the sequence from 1–56.
B. Fragment 2, DOMON domain, sequence spanning from 57–173. C. Fragment 3, the connecting loop between the DOMON domain and the
monooxygenase domain, spanning the sequence from 174–195. D. Fragment 4, the N-and C-terminal monooxygenase domains, spanning the
sequence from 196–526. E. Fragment 5, the C-terminal region. F and G depict the orientation of fragment 3. F. Modeled structure from sequence
position 1–173; with region 1–56 highlighted in red and DOMON domain (57–173) colored green. No b-strand is seen in the region 51–53 as indicated
by arrow. G. Modeled structure from sequence position 1–197; with region 1–56 highlighted in red and DOMON domain (57–173) shown in green;
fragment 3 depicted in blue. b-sheet is shown in black color between 51–53 and 193–197.
doi:10.1371/journal.pone.0026509.g005
First 3D Model of Human DBH
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26509lies in allowed region (favored + allowed regions) and rest of them
are outliers. However, this can be expected as 60% of structure is
predicted to be loop and Ramachandran plot does not define values
for the residues in loop regions. It can be seen from Table S2 that
almostall the outlierresiduesbelongtoloop region. Thus,DBHwas
modeled using experimental information in conjunction with
computational techniques and manual intervention.
Active Site Structure - Introducing two Cu atoms
EPR and EXAFS studies have shown the coordination for two
Cu atoms in the oxidized state to be CuA(His)3(H2O) and
CuB(His)2X(H2O), where X is either His or O-donor ligand or
solvent [21]. The imidazole groups are located at 1.99 A ˚ from Cu
atom whereas the O-donor groups reside at an average distance of
1.94 A ˚. Using these data and homology with PHM (PDB-ID:
1PHM), the two Cu atoms were introduced in the modeled
structure as shown in Figure 7a. At the CuA binding site (purple
sphere), His262, His263 and His333 interact with Cu atom
through their delta nitrogen atom (ND1) and are present at
1.96 A ˚, 1.97 A ˚, and 2.07 A ˚, respectively, from Cu center. These
distances are similar to those reported by EPR investigation.
Similarly, at the CuB binding site (green sphere), His412 and
His414 interact with Cu atom through their epsilon nitrogen atom
(NE2), and are present at 2.08 A ˚ and 2.02 A ˚ respectively, from Cu
center. These distances in the model are also in reasonable
agreement with those observed from experiments as mentioned
above thus providing confidence in the model. X, whose ligand
identity is unknown, was estimated to be located at 2.56 A ˚ from
Cu atom through biochemical studies [24]. It is impossible to
identify what X is in an in silico model and would await final
confirmation only from X-ray crystallographic studies. We did not
observe any (O/N) amino acid ligand at 2.5–3 A ˚ in our model.
The possibility remains that the ligand is a solvent molecule.
However, both His439 and Gln486 are likely candidates being
located at ,6A ˚ away from CuB, provided the ligand X is
contributed by the polypeptide. It is interesting to note, that both
His439 and Gln486 are highly conserved in primary structure,
which argues for a very special role for these two amino acid
residues. Any requisite conformational change could bring these
two residues within the distance observed experimentally. Two
water molecules, shown as red spheres in Figure 7a were also
introduced at the two Cu sites at 1.94 A ˚ distance from Cu.
It has been reported, however, that in the reduced state of the
enzyme, there are dramatic changes in DBH protein structure
[21–24]. The two water molecules mentioned above are lost and
the Cu atoms are present in reduced coordination state (less than
Figure 6. Complete model of human DBH enzyme and its experimental validation. (A) Residues forming disulfide links in the model are
colored by atom type (carbon is cyan, nitrogen is blue, oxygen is red and sulfur is yellow). (B) Circular dichroism of DBH enzyme predicted from the
model. The predicted spectra matches well with experimental circular dichroism spectrum of bovine DBH [44] .
doi:10.1371/journal.pone.0026509.g006
First 3D Model of Human DBH
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simulation of conformational changes to mimic the reduced state
of the enzyme. In such a state, CuB coordinates with a S atom
from Met487 present at 2.23 A ˚ [24]. In the oxidized state in our
model, Met487 does not coordinate with Cu atom and is present
at 2.93 A ˚ in the structure (Figure 7a). Such strategic and proximal
placement of Met487 does indicate that on conformational change
typical of reduced state the S atom could move closer to the CuB
atom, thus corroborating experimental finding. Such a movement
can eliminate water away from active site pocket and reduce
coordination state of Cu below 4. Despite the requirement for two
Cu centers per catalytic unit, there is no evidence for short-range
magnetic interaction and hence each Cu (II) center is believed to
be mononuclear. A lower limit of 7 A ˚ is defined between the two
Cu centres [31] and the proposed model shows that indeed the Cu
sites are 10.27 A ˚ apart. Between the two Cu sites is a typical cleft
that is fully accessible to solvent, which probably links the two Cu
sites. Figure 7b highlights the active site cleft with the two Cu
centers along with their metal binding residues and the residues
Glu265, Glu366 and Tyr491 that are suggested to play important
role in the catalysis of the enzyme [28].
Quaternary Structure
It has been shown that the two subunits form a dimer connected
through interchain disulfide link between Cys528A-Cys528B and
Cys530A-Cys530B [25]. Figure 8a shows the probable dimer
Figure 7. Active site architecture of DBH. A. Distance between the metal binding sites and Cu atoms are highlighted. CuAis depicted as purplesphere;
CuB is depicted as green sphere. Two water molecules are represented as red spheres. Metal binding residues are colored by atom type (carbon is cyan,
nitrogen is blue, oxygen is red and sulfur is yellow). B. Active site cleft along with the active site residues highlighted. Also, shown are Glu265, Glu366 and
Tyr491, residues that play important role in catalysis. Residues are colored by atom type (carbon is cyan, nitrogen is blue, oxygen is red and sulfur is yellow).
doi:10.1371/journal.pone.0026509.g007
First 3D Model of Human DBH
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optimum geometry, linked through the two disulfide bonds
mentioned above. The dimers are held through non-covalent
interaction to form the tetramer, which is known to be the active
unit of the enzyme [19]. Figure 8b shows the probable tetramer
structure for the soluble form of the enzyme in which each subunit
lacks the signal peptide. The subunits are not very intricately
woven, but seem to be adjacent and planar. This presents the first
oligomeric structure for DBH. Figure 8c highlights the residues
involved in interface formation and provides an image of the
subunit interface. Table 1 lists the residues involved in interface
formation. Different non-bonded interactions like hydrophobic
contacts, electrostatic interactions, interchain H-bonds and salt
bridges were inspected for interface identification. Almost all the
residues involved in interface formation are conserved across the
species showing significant alignment implying that the tetramer
structure adopt almost similar fold and is significant to the
physiological function of the enzyme. It is obvious that the
DOMON domain can potentially promote tetramerization of the
subunits. The DOMON domain alone contributes almost 26% of
the interface amino acids. On the other hand, the C-terminal
domain could be important for dimerization of the enzyme since
the two disulfides that force interchain linkage are both present in
the C-terminal domain. The flexibility in this region could
facilitate the subunit recognition and interaction.
Physicochemical validity of the model
A preliminary physicochemical test of the validity of the model
was achieved by comparing the experimental partial specific volume
of DBH with the one calculated using soluble form of the computed
model.The predicted values ofpartial specificvolumeare 0.758 ml/
g (with volume=8.17589e-20 ml calculated using
3V server) and
0.770 ml/g(withvolume=8.3126e-20 mlcalculatedusingVADAR
server) which are comparable to the experimentally known value for
bovine DBH (0.731 ml/g) and human pheochromocytoma DBH
(0.72 ml/g) [43]. A further confirmatory test involved comparison of
experimental and calculated circular dichroism (CD) spectrum of
DBH. The CD spectrum predicted from DBH model is shown in
Figure 6B. The calculated spectrum is comparable in both overall
shape (with a single negative peak at 219 nm) and maximum
ellipticity value (approximately 25900 deg.cm
2/dmole) to the
experimental spectrum for bovine DBH (single negative peak at
Figure 8. Models for oligomer structures of DBH. A. Model for the dimeric form of DBH. Chain A and B are shown in blue and red, respectively.
B. Model for the tetrameric form of the enzyme. Chain A, B, C, and D are depicted in blue, red, green and purple respectively. C. Residues forming
tetramer interface. Subunits are highlighted in tube conformation with chains A, B, C, and D highlighted in blue, red, green and yellow, respectively.
Residues are represented in SURF conformation with colors same as that of corresponding chain color.
doi:10.1371/journal.pone.0026509.g008
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26000 deg.cm
2/dmole) reported previously [44]. Such tests prove
that the in silico model proposed in the present investigation is valid.
The minor differences in negative wavelength maximum for
predicted CD spectrum is acceptable and statistically not significant
since the prediction algorithm is not perfect (as seen when known
crystal structures of model proteins failed to reproduce the
experimental CD spectrum to perfection; figures not shown).
Moreover, no CD spectrum for human DBH is yet known, and
the comparison performed here was with bovine DBH, whose
experimental CD spectrum might have differences from its human
homologue, resulting in the observed differences in the predicted
spectrum.
Single Nucleotide Polymorphism
A number of SNPs are known to exist within coding regions those
results in synonymous changes in the amino acid sequence of the
enzyme [12,45]. Identifying the location of these SNPs within the
structure of the enzyme and their interactions with neighboring
amino acid residues is critical in determining their functional
significance. Knowledge of the effect of these SNPs on the activity
of the enzyme can help with rational drug design. Eighteen of such
SNPs were studied as listed in Table 2 along with their neighboring
residues within 6 A ˚ radius of the concerned SNP. Tetramer is known
to be the active form of DBH whereas no activity is reported in the
dimer or monomer form. Hence, SNPs close to active site region or
the ones present in the (or near the) interface region of the tetramer
Table 1. Residues involved in tetramer interface formed by different non-bonded interactions.
Interchain
H-bonds Salt Bridge Electrostatic Interactions Hydrophobic Interactions
Glu576A–
Thr254D
Glu381A–
Lys451D
Chain A Thr139,Pro140,Glu141, Gly142,Phe241,Val253,
Lys286,Arg291,Pro322, Gly323,Arg326,Val370, Tyr371,Pro373,Val374,
Pro379,Arg380,Val478, Gln574,Gly575,Glu576, Trp577,Leu579
Chain A Glu141,Phe241,Arg291, Pro322,Val374,Arg380,
Arg572,Gln574,Gly575, Trp577
Arg326A–
Glu60D
Arg326A–
Glu60D
Chain B Leu77,Arg79,Pro140, Lys451 Chain B Glu60,Leu77,Arg79, Pro140
Lys567A–
Glu141D
Chain C Gln135,Gln137,Pro140, Lys148,Met190,Ile340,
Val527,Cys528,Gly614, Lys616
Chain C Gln137,Met190,Val527, Cys528,Ile612,Gly614, Lys616
Arg572A–
Glu141D
Chain D Asp54,Pro55,Glu56, Gly57,Glu60,Gln75, Leu77,Arg80,Glu141,
Ile252,Val253,Thr254, Glu258,Gly305,Lys307, Phe309,Val527,Cys528
Chain D Pro55,Glu56,Gly57, Gln75,Leu77,Glu141,
Ser179,Val253,Phe309
Arg291A–
Glu258D
Glu141B–
Lys616C
Salt bridge identification was performed with cut off distance of 7 A ˚. Electrostatic interactions were determined within 4 A ˚ distance.
doi:10.1371/journal.pone.0026509.t001
Table 2. SNPs causing synonymous changes in protein and neighbouring residues within 6 A ˚ radius.
SNPs Residues in 6 A ˚ radius
Gly12RSer12 Ser9,Leu10,Pro11,Gly12,Pro13,Ser14,Met15,Arg16
Arg16RTrp16 Pro11,Gly12,Pro13,Ser14,Met15,Glu17,Ala18,Ala19,Phe20
Gly88RAla88 Leu86,Phe87,Met89,Ser90,Gly93,Glu94,Leu95,Ala98,Asp99,Leu100,Val101, Leu168,Val169,Tyr170
Asp106RAla106 Trp104,Thr105,Gly107,Asp108,Thr109,Arg138
Glu181RGln181 Phe29,Ile32,Leu33,Pro52,Leu53,Asp54,Lys82,Ile172,Leu173,Ser179,Leu180, Ala182,Pro200
Asn201RSer201 Phe177,Arg178,Leu198,Lys199,Pro200,Ile202,Pro203
Ala211RThr211 Leu207,Pro208,Ser209,Asp210,Ala211,Cys212,Thr213,Tyr353,Thr354, Ala355
Lys239RAsn239 Leu237,Pro238,Gly240,Phe241,Ser242,His244
Glu250RGln250 Lys248,Tyr249,Pro251,Ile252,Ile349,Arg350,Tyr352
Asp284RAsn284 Pro282,Cys283,Ser285,Lys286,Phe481
Asp290RAsn290 Pro271,Lys288,Pro289,Arg291,Leu292,Gln574,Gly575,Glu576
Leu317RPro317 His245,Ile246,Tyr249,Gln268,Ala315,Gly316,Ala318,Phe319,Asn361, Ala362
Ala318RSer318 Arg243,His244,His245,Ile246,Gly316,Leu317,Phe319,Gly320,Ser324, Asn361
Asp460RAsn460 Asp392,Leu424,Val425,Arg426,Val456,His457,Pro458,Gly459,Val461, Leu462
Thr467RMet467 Phe384,Ile385,Leu386,Gly417,Arg418,Lys419,Ser465,Cys466,Tyr468, Asn469
Gly482RArg482 His414,Gly480,Phe481,Ile483,Leu484,Glu485,Met487
Trp544RSer544 Trp431,His517,Leu518,Val542,Pro543,Asn545,Ser546, Phe547,Asn548
Arg549RCys549 Asp427,Gly428,Arg429,Glu430,Leu518,Pro543,Trp544,Asn545,Ser546, Phe547,Asn548,Arg549,Asp550,Val551, Leu552,Lys553,Ala554,Tyr556
doi:10.1371/journal.pone.0026509.t002
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Change in amino acid at position 318 from Alato Ser was reported to
have no effect on the activity of the enzyme [7], while another group
[18] reported the contrary. Ala318, as evident from Figure 9a, is
present in a region distant from the copper binding sites, opposite to
the active site cleft and thus may not have any effect on the activity.
This finding confirms the first report and provides a structural basis to
the contradictory results. Similarly, the Leu317RPro317 substitution
is not expected to affect enzymeactivity. However, substitution of Gly
to Arg at position 482 may have subsequent effect on the activity of
the enzyme as it is present close to the active site, right at the opening
of the cleft (Figure 9a). As can be seen from Table 2, active site
residues His414 and Met487 are present within 6 A ˚ radius of this
residue and could indirectly influence DBH function as well. Other
SNPs that might have functional significance are Glu181R Gln181,
Lys239RAsn239, Glu250R Gln250, and Asp290RAsn290 as they
are located near the interface of the tetramer as shown in Figure 9b.
Substitution of Arg549 with Cys might also have functional
significance as the Cys is surface exposed and might be involved in
random interchain disulfide links resulting innon-native dimerization
[13] (Figure 9c). Other SNPs listed in Table 2 do not seem to be as
important for the activity of the enzyme, as neither are they close to
active site region nor to the tetramer interface.
Analysis of substrate binding
DBH shares 27% sequence similarity with PHM. Positions
c o r r e s p o n d i n gt of i v eH i sr e s i d u e sa n do n eM e tr e s i d u ei n v o l v e di n
metal binding are very well conserved. The position of Cys residues
forming disulfide links is conserved as well. The structure and
mechanistic data of PHM were thus extended to the monoxygenase
domain of rat DBH (modeled using the structure of rat PHM as a
template) to display the position of the catalytically important residues
in DBH [28]. In the rat DBH model, residues Glu265, Glu366,
Gln410 and Tyr491 (numbering based on Human DBH sequence)
were shown to form H-bonding network with dopamine that
stabilized the substrate interaction. However, the interaction of
Tyr491 with dopamine was dubious as substitution of this Tyr with
Phe through site-directed mutagenesis in rat PHM yields active
enzyme with little effect on its activity [28]. Figure 10a highlights the
rat DBH (in red; modeled using 1PHM as template) and modeled
human DBH structures along with the four residues (Glu265, Glu366,
Gln410 and Tyr491) thought to be important in catalysis. The two
superposed structures show a marked deviation in the orientation of
the loop (encircled in Figure 10a) located close to the active site region.
As a result His297 is located close to the Glu366 residue in human
DBH and restricts the dopamine hydroxyl group from facing upward.
In contrast, the corresponding His residue (His300) in rat DBH faces
away from Glu366 as shown in Figure 10b. Hence it is essential to
investigate human DBH in details without relying solely on rat DBH.
Figure 10c highlights the interaction of the enzyme with the substrate
in the structure of human DBH/dopamine complex where dopamine
was docked manually. Similar hydrogen bonding network can be seen
as demonstrated by Prigge et al. [28] for rat DBH. However,
Figure 9. Mapping SNPs on the DBH structure. A. Shown are the position of SNPs Leu317, Ala318 and Gly482. The two Cu atoms are
represented as red spheres. B. Shown are the position of SNPs Glu181, Glu250, Lys239 and Asp290 located near the interface of chain A and D.
Interface is shown as SURF conformation with chain A colored blue and chain D in yellow. C. Arg549 is exposed to surface. Its substitution to Cys may
result in disulfide-based oligomerization. Residues are colored by atom type (carbon is cyan, nitrogen is blue, oxygen is red and sulfur is yellow).
doi:10.1371/journal.pone.0026509.g009
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dopamine and the distance between them is 4.56 A ˚, large for H-bond
to form (Figure 10c). This emphatically explains why no change in
enzyme activity was observed experimentally when Tyr491 was
mutated [28], as mentioned above. This signifies and strongly
validates the model since it can faithfully corroborate experimental
findings. Furthermore, the model shows that His297 contributes
immensely in stabilizing the dopamine by forming a hydrogen bond as
shown in Figure 10c. His297 is also well conserved across the species
and our finding provides a structural rationale for such conservation.
Mode of Inhibitor Binding
Diseases such as congestive heart failure can be treated by DBH
inhibition, whichdirectly modulates sympathetic nerve function [6].
Onesuchnovel,selectiveandpotentdrug identified forinhibition of
DBH is nepicastat [11]. Preclinical studies have shown that
nepicastat produces gradual modulation of sympathetic nervous
systembyinhibiting thebiosynthesisofnoradrenaline [6].However,
lack of proper three-dimensional structure of DBH has precluded
structural investigation of the complex between the enzyme and the
inhibitor and the understanding of the mechanism of inhibition. In
order to gain insight into the structural aspect of inhibition,
nepicastat was docked to the soluble form of DBH model. Out of
several putative complexes obtained, we inspected one where
nepicastat docked in the active site cleft with acceptable energy
parameters. As shown in Figure 10d, nepicastat is sandwiched
between the two Cu centers and is involved in hydrogen bonding
interaction with the OE1 atom of Glu265. Unlike dopamine,
nepicastat is not involved in a network of H-bonding though a
multitude of His residues form a cage around the molecule.
Conformational changes concomitant to binding can induce further
interactions with one or more His residues. Furthermore, while
nepicastat binds towards the opening of the active site channel,
dopamine prefers binding towards the inside of the cleft. The
external binding provides nepicastat with an easy access to the
enzyme and leaves scope for designing analogues or addition of
chemical groups that can enhance binding through more extensive
hydrogen bonding or other non-covalent interaction which in turn
can improve specificity and affinity of binding.
Conclusion
The enzyme was investigated for almost three decades now that
has resulted in a wealth of biochemical information. However,
surprisingly, structural investigation has been rare and no three-
Figure 10. Residues important for catalysis. A. Active sites for rat DBH and human DBH superposed. Difference in the loop orientation located
near the active site region is highlighted. Shown are the residues Glu265, Glu366, Gln410 and Tyr491. Both the models are depicted in tube
conformation with rat DBH shown in red and human DBH in blue. Metal binding residues are colored by atom type (carbon is cyan, nitrogen is blue,
oxygen is red). B. Difference in the orientations of active site residue His300 from rat DBH and His297 from human DBH. C. Residues involved in
hydrogen bonding with the substrate dopamine. The hydrogen bonds are highlighted in light pink along with their distances. The distance between
Tyr491 and dopamine is highlighted in yellow and is too long to form proper hydrogen bond. D. A potential drug, nepicastat docked to human DBH.
Nepicastat is shown sandwiched between the two Cu centers and the highlighted His residues. The inhibitor hydrogen bonds to Glu265.
doi:10.1371/journal.pone.0026509.g010
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The current investigation presents the first structure of DBH, albeit
in silico, and lays the foundation for a repertoire of other
investigation that would include further computational studies
(viz. simulation of structures to highlight conformational changes),
rational protein engineering, functional evaluation of SNPs, drug
design, structure-function relationship, etc. Infact, the in silico model
hints at why experimental structure might not have been obtained
and why crystallography could be difficult. The structure seems to
contain a large number of flexible loops that would inhibit the
formation of diffractable crystals and would preclude good quality
electron density development in the X-ray diffraction data. We also
presenthere the first image of DBHin dimericand tetrameric forms
and the possible role of individual domains other than the catalytic
domains. The C-terminal domain probably controls dimerization
while the DOMON domain promotes tetramerization. This work
shows that three-dimensional structure could possibly be built using
biochemical information in conjunction with simple in silico tools
and manual intervention; a new approach to structure solution.
Here a subset of biochemical information has been used to orient
the protein conformation, while several other biochemical data was
corroborated from the structure indicating the internal consistency
and accuracy of the method. The physicochemical tests corroborate
the validity of the model as well. The most dramatic success has
been the way the model showed why Tyr491 mutation resulted in
no change in enzyme activity, a fact that eluded justification of the
experimental finding for long. Similarly, it provided a structural
basis to the evolutionary conservation of residue His297, which
otherwise would have been difficult to understand through
experimental means. The strength of the model thus lay in its
ability to corroborate several experimental results. The model also
provides several testable hypotheses especially with regard to the
functional implications of several exonic SNPs. Site-directed
mutagenesis is a simple way to test such predictions and the authors
are pursuing such experimental necessities. The current investiga-
tion has resolved controversial results regarding the influence of
certain SNPs on enzyme activity as well. The structure highlighted
the mechanism of ligand stabilization and detailed primary
structure analysis has revealed that amino acid residues responsible
for intricate hydrogen bonding network and stabilization of the
substrate in the catalytic site are highly conserved. Similarly, we
have shown that the disulfides in the structure as well as the residues
involved in interface formation are conserved across species. The
conservation of interface residues argue that oligomerization of
DBH subunits is important for the activity and function of the
enzyme. The model paves the pathway for in silico drug design. For
example, in case of the promising therapeutic inhibitor nepicastat,
one can envisage that design of suitable inhibitor analogue or
chemicalmodificationcould potentiallyinducemultipleinteractions
with neighboring residues as opposed to a single hydrogen bond,
which in turn can result in enhancement of specificity and strength
of inhibition. The model has shown subtle differences in its catalytic
site from that of rat DBH, which otherwise would have been
obscure.
The model indeed suffers from some weaknesses as well. There
has been high dependence on the accuracy of secondary structure
predictions. It cannot still account for one disulfide bond, which
could be due to the fact that in solution determination of the
number of disulfides bonds was erroneous, or that the model needs
further refinement and support from X-ray crystallographic studies.
The authors are currently focused on the later possibility. Another
intrinsic weakness includes random selection of torsion angles to fit
the experimental data that may not be the most optimal possible
conformation. For this, the testable hypotheses emerging from the
study need to be verified experimentally. Nevertheless, the model
has successfully corroborated several experimental findings and is
expected to boost further investigations.
Methods
Anassortment ofcomputationaltechniques,includingautomated
homology and ab-initio modeling, and manual model building were
used to map the three-dimensional structure of the protein. The
amino acid sequence of human DBH (accession number: P09172)
was obtained from NCBI (www.ncbi.nlh.nlm.gov). DBH sequences
from several other species were similarly obtained. Figures were
rendered using VMD or Swiss-PDB Viewer [46,47].
Sequence Analysis, Domain Characterization and
Secondary Structure Prediction
To identify sequences similar to DBH, protein sequence search
was performed using the BLAST program from NCBI available at
www.ncbi.nlm.nih. gov/BLAST [48] based on an earlier report
[37]. Domain analysis of sequence was accomplished using
the Conserved Domain Architecture Retrieval Tool (CDART)
from NCBI available at http://www.ncbi.nlm.nih.gov/Structure/
lexington/lexington.cgi [38].
Computation of various physical and chemical parameters for
the protein sequence was done using the ProtParam tool from
ExPASy available at http://www.expasy.ch/tools/protparam
[49]. DBH protein sequences known from twelve organisms
including humans were aligned (multiple sequence alignment)
using ClustalW program [50] available at http://align. Genome.
jp. Secondary structure prediction was done using PredictProtein
tool from ExPASy (http://www.predictprotein.org) [51].
Model Building and Validation
Homology modeling tools (EsyPred3D, http://www. fundp.ac.
be/sciences/biologie/urbm/bioinfo/esypred/, [52]) and thread-
ing methods (Phyre, http://www.sbg.bio. ic.ac.uk/,phyre/, [53])
of model building failed owing to lack of proper template that
could provide reference coordinates for full-length protein.
Instead, a combination of ab-initio tool and manual calculations
were used to build a complete model for the enzyme structure.
The protein sequence was divided into shorter amino acid
stretches such that each stretch represented sequence of one or
more than one domain. A total of five such amino acid stretches
were considered with fragment 1 spanning the sequence from 1–
56, fragment 2 from 57–173, fragment 3 from 174–195, fragment
4 from 196–526 and fragment 5 from 527–617. The polypeptide
fragments were then modeled individually by ab-initio methods
using I-TASSER server for protein structure prediction available
at http://zhang. bioinformatics.ku.edu/I-TASSER [54–56]. For
fragment 4, however, the model was obtained through homology
modeling using rat PHM crystal structure (PDB ID: 1PHM) as
template. To obtain the complete structure, individually modeled
fragments 1, 2, 3 and 5 were assembled manually around fragment
4 with several biochemical properties of the protein as guiding
milestones. The assembly of the fragments was performed using
Swiss-PDB Viewer by first reproducing the v, y and Q angles from
modeled fragments to the extended polypeptide chain (617 amino
acid) and then changing the torsion angles wherever necessary
based on the secondary structure prediction details and location of
disulfide bridges. Fragments were thus oriented to conform to
available experimental data (like disulfide linkages). Close contacts
between atoms and geometrical incompatibility were also
considered.
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out in vacuo with the GROMOS96 43B1 parameters, a module of
Swiss-PDB Viewer, set without reaction field with different number
of cycles for steepest descent and conjugate gradient runs, to relax
the structure and remove any bad contacts. The model was
subsequently validated using WHATIF validation server available
at www.cmbi.kun.nl/WIWWWI/, [57]. Assessment of Ramachan-
dran plot was accomplished using Rampage available at http://
mordred.bioc.cam.ac.uk/,rapper/rampage.php, [58].
DBH is known to contain two Cu atoms per subunit [19,59,60]
and the metal coordination and metal geometry has been studied
in extensive details [20,21,28,30–35]. Using these experimental
data coordinates for the two Cu atoms were manually introduced
into the structure. Two water molecules were also introduced
around the Cu atoms conforming to experimental finding.
Calculation of partial specific volume and circular
dichroism spectrum
Partial specific volume and circular dichroism (CD) spectrum
were calculated for the soluble form of the DBH model for
comparison with experimental parameters [44]. Partial specific
volume was calculated as ratio of protein volume to its molecular
weight. Protein volume for the model was calculated using two
different web servers,
3V server available at http://3vee.
molmovdb.org/index.php [61] with 1.4 A ˚ probe radius and
VADAR available at http://vadar.wishartlab.com/ [62].CD
spectrum for the model was calculated using DichroCalc available
at http://comp.chem.nottingham.ac.uk/dichrocalc/ [63].
Quaternary Structure Modeling of DBH
Subsequent to model building, the quaternary structure of the
enzyme was also obtained in silico. It is known that the soluble
enzyme tetramer is formed by non-covalent interactions between
dimers [19,27]. As such, DBH tetramer was constructed using
four identical smaller subunits i.e, with the signal sequence
removed (soluble form of the enzyme). It was been shown that
two subunits in each tetramer are held together by two interchain
disulfide bonds to form dimer [25]. The dimers were thus
obtained by docking two units of monomer model obtained as
above on each other using zDOCK [64] server available at
http://zdock.bu.edu/ and specifying Cys528 and Cys530 as
binding sites. However, zDOCK generated an output file with
the binding sites facing each other but without a proper disulfide
bond. The subunits in the dimer thus obtained were oriented
using Swiss-PDB Viewer by rotating and translating them such
that the disulfide bonds are formed with correct orientation and
proximity. Several permutations and combinations were tried
and the best geometrical and stereochemical fit was considered.
Tetramer was subsequently modeled by docking the dimers
on each other using PatchDock protein docking server available
at http://bioinfo3d.cs.tau.ac.il/ Patch Dock [65]. The structure
was further refined with FireDock (http://bioinfo3d.cs.tau.ac.il/
FireDock, [66,67].
Tetramer Interface Identification
The non-bonded interactions in the tetramer were identified to
determine the residues involved in tetramer interface formation.
Hydrophobic interactions were identified by using MolProbity
server available at http://molprobity.biochem.duke.edu/ [68].
First, all atom contacts were identified and screened for carbon-
carbon contacts between the subunits. These C-C contacts were
then considered as making hydrophobic contacts. Residues
involved in electrostatic contacts were identified with a distance
cut-off of ,4A ˚ [69]. Interchain hydrogen bonds were determined
using Swiss-PDB Viewer. Salt bridge identification was done using
WHATIF web server available at http://swift.cmbi.ru.nl/servers/
html/index.html, which considers charge interactions only over an
interatomic distance less than 7 A ˚.
Mapping of SNPs
The model thus obtained was analyzed to gain insight into
structural characteristics. A number of exonic SNPs resulting in
non-synonymous mutations in the protein, known in literature,
were mapped on the three-dimensional model of DBH to
understand their functional significance. Hypotheses were formu-
lated as to their influence on enzyme activity, oligomerization and
stability based on their location in the structure. Site directed
mutations were obtained in silico using Swiss-PDB Viewer and
residues within 6 A ˚ radius of the target SNP were determined.
Docking of Enzyme Substrate
Finally, the dopamine bound conformation of the enzyme was
built manually to study the interaction of the substrate with the
enzyme, in a manner similar to that reported by Prigge et al. [28]
using partial model of rat DBH to determine catalytically
important residues. The partial model of rat DBH (modeled using
rat PHM, PDB ID: 1PHM) was compared with the human DBH
model to deduce the differences in structure, if any, of the catalytic
core and subsequently highlight the difference in orientation and
conformation of the catalytically important residues in human
DBH that are important for substrate binding.
Docking of Inhibitor
The potentially therapeutic inhibitor nepicastat was docked on
DBH model using PatchDock protein docking server available at
http://bioinfo3d.cs.tau.ac.il/PatchDock. Soluble form of the
enzyme was used as an input receptor structure, as it is the
functional form of DBH. The three-dimensional molecular file
for nepicastat was obtained from ChemSpider (http://www.
chemspider.com; ChemSpider ID for nepicastat: 7971947), which
was then converted into pdb format using file conversion program
MN.CONVERT available at http://www. molecular-networks.
com. The pdb file thus obtained was used as an input ligand
structure for docking by PatchDock.
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